Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 11:04 AM ET


Company Overview of Intas Pharmaceuticals Ltd.

Company Overview

Intas Pharmaceuticals Limited engages in the development, manufacture, and marketing of pharmaceutical formulations worldwide. The company provides products in various therapeutic areas, such as neurology, psychiatry, cardiology diabetology, urology, nephrology, and pain management. It offers a portfolio of biosimilar products across microbial and mammalian cell culture products, such as Neukine, Erykine, Intalfa, Pegasta, Terifrac, Mabtas, and Folisurge, as well as plasma derived products, which are under various stages of development. The company also operates in animal health care industry and provides a range of products, including anti-parasites, skin care, anti-infectives, nutraceutica...

Chinubhai Centre

Off Nehru Bridge

Ashram Road

Ahmedabad,  380009


Founded in 1985


91 79 2657 6655


91 79 2657 8862

Key Executives for Intas Pharmaceuticals Ltd.

Chief Executive Officer, Managing Director, Director, Member of Share Allotment Cum Transfer Committee, Member of Investor Grievance Committee, Member of IPO Committee and Member of CSR Committee
Age: 54
Founder and Chairman
Age: 82
Chief Finance Officer, Member of Share Allotment cum Transfer Committee and Member of IPO Committee
Age: 51
Vice Chairman, Managing Director, Chairman of Compensation Committee, Member of Share Allotment Cum Transfer Committee, Member of Audit Committee, Member of Investor Grievance Committee, Member of IPO Committee and Member of CSR Committee
Age: 51
Managing Director, Executive Non Independent Director and Member of CSR Committee
Age: 56
Compensation as of Fiscal Year 2015.

Intas Pharmaceuticals Ltd. Key Developments

Intas Pharmaceuticals Not Seeking Listing

Intas Pharmaceuticals Ltd. is not seeking listing. "We don't feel the need to consider a listing for the next one to two years at least," chief financial officer Jayesh Shah said. "When we are thinking of it, we will explore all options, including an overseas listing."

Intas Pharmaceuticals Launches Biosimilar Version of Ranibizumab in India

Intas Pharmaceuticals announced that it has launched a "biosimilar" version of Roche's Lucentis (ranibizumab) in India. The biosimilar is marketed under the brand name Razumab and will reportedly be sold at a discount of some 25% against imported Lucentis. Lucentis is indicated for the treatment of wet age-related macular degeneration, macular oedema following retinal vein occlusion, and diabetic macular oedema. It remains unclear, however, for which of these indication Razumab is indicated. Significance:With details of the pathway used for the approval and the clinical data used to support its application remaining limited it is challenging to determine if Razumab is a biosimilar - i.e. in line with the definition of biosimilars in regulated markets. The company currently markets a growing portfolio of biosimilar products in India, including biosimilar erythropoietin, filgrastim, pegylated filgrastim, and rituximab. Launching in regulated markets does however require significant finances to conduct the clinical research needed to support market access and the marketing know-how to support market uptake once approved. Despite these challenges the company has launched a biosimilar version of Amgen's Neupogen (filgrastim) in Europe. It is important to note that the clinical data and marketing knowledge needed to launch a monoclonal antibody is substantially more significant than that needed to launch a less complex biologic such as filgrastim. In India, even with a 25% discount, the biosimilar may be out of reach for many in India's largely out-of-pocket market. This point, coupled with a preference for western brands among the wealthy, means that the market potential for Razumab in India may be limited.

Intas Launches Biosimilar Version of Amgen's Neupogen in Europe

Intas has launched a biosimilar version of Amgen's (US) neutropaenia drug Neupogen (filgrastim). The injectable drug is the first biosimilar manufactured by an Indian company to be approved in the tightly regulated EU market. According to a company statement, Phase III clinical trials (multi-centre safety and efficacy studies involving 120 female adult patients receiving chemotherapy to treat breast cancer) showed that Intas's filgrastim reduced severe neutropaenia to 1.4 days from an average of 1.6 and 1.8 days reported in other studies. Intas has confirmed that its lower-cost version of filgrastim, marketed under the brand name Accofil, has secured UK and Dutch tendering contracts, and expects to launch in Mexico and Brazil in the next six months. The company is looking to file for US approval in 2016, but would face competition at launch from Sandoz (subsidiary of Swiss firm Novartis), which has already filed for approval for Zarxio, another biosimilar version Neupogen. It is anticipated that the US FDA is likely to make a final decision regarding the approval of Zarxio in March.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intas Pharmaceuticals Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at